Ambrx Biopharma Current Ratio 2020-2023 | AMAM

Ambrx Biopharma current ratio from 2020 to 2023. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Ambrx Biopharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2023-03-31 $0.16B $0.02B 10.13
2022-12-31 $0.09B $0.02B 5.44
2022-06-30 $0.12B $0.03B 4.70
2022-03-31 $0.00B 0.00
2021-12-31 $0.18B $0.03B 7.19
2021-06-30 $0.17B $0.02B 9.90
2020-12-31 $0.09B $0.01B 7.02
2019-12-31 $0.02B $0.02B 1.22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.824B $0.007B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.584B 22.35
Ginkgo Bioworks Holdings (DNA) United States $3.379B 0.00
Arcus Biosciences (RCUS) United States $1.536B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.191B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00